Canakinumab treatment of patients with stable CAD, with a history of previous MI and increased hsCRP, resulted in a reduction in cardiovascular events, highlighting the contribution of the IL-1 pathway to cardiovascular risk [147]. This evidence concerns the gene IL1A and coronary artery disorder.